SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14188
Abstract: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed… read more here.
Keywords: amyloid cardiomyopathy; inhibitor therapy; transthyretin amyloid; sglt2 inhibitor ... See more keywords
DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Prescriber"
DOI: 10.1002/psb.1626
Abstract: DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article… read more here.
Keywords: inhibitor combined; dpp sglt2; sglt2 inhibitor; combined therapy ... See more keywords
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Sign Up to like & getrecommendations! Published in 2022 at "Current Diabetes Reports"
DOI: 10.1007/s11892-021-01442-z
Abstract: Purpose of Review This review offers a critical narrative evaluation of emerging evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective effects in people with type 2 diabetes. Recent Findings The SGLT2 inhibitor class of glucose-lowering… read more here.
Keywords: protection sglt2; sglt2 inhibitors; sglt2; renal protection ... See more keywords
The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Therapy"
DOI: 10.1007/s13300-017-0248-5
Abstract: AbstractIntroduction Sodium glucose co-transporter 2 (SGLT2) inhibitors increase urinary glucose excretion (UGE) by reducing the renal threshold for glucose excretion, which results in decreased serum glucose concentrations in patients with type 2 diabetes mellitus (T2D).… read more here.
Keywords: sglt2 inhibitor; urinary glucose; morning spot; morning ... See more keywords
GLP1 receptor agonist and SGLT2 inhibitor combination: An effective approach in real-life clinical practice.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2019.12.012
Abstract: PURPOSE The aim of this study was to evaluate the effectiveness and safety of combination therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor and a glucagon-like peptide-1 receptor agonist (GLP1RA) in patients with inadequately controlled type… read more here.
Keywords: receptor agonist; combination; inhibitor combination; sglt2 inhibitor ... See more keywords
Comparison of the Effects of Insulin and SGLT2 Inhibitor on the Renal Renin-Angiotensin System in Type 1 Diabetes Mice.
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2020.108107
Abstract: AIMS SGLT2 inhibitors have been proposed as an adjunct to insulin therapy for glycemic control in type 1 diabetes (T1D) patients. However, concern has been raised due to an increase in renin-angiotensin-system (RAS) activity reported… read more here.
Keywords: insulin; sglt2 inhibitor; akita mice; mice ... See more keywords
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2018.04.024
Abstract: Abstract Diabetic nephropathy is the leading cause of end‐stage renal disease in the world. Although recent development of sodium‐glucose cotransporter (SGLT) 2 inhibitors offers a new antidiabetic therapeutic strategy, it remains unclear whether such treatments… read more here.
Keywords: ipragliflozin; sglt2 inhibitor; type diabetic; diabetic nephropathy ... See more keywords
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents
Sign Up to like & getrecommendations! Published in 2018 at "Life Sciences"
DOI: 10.1016/j.lfs.2018.02.009
Abstract: Aims: Daily intake of carbohydrates differs among individual patients with type 2 diabetes. Here, we investigated whether or not dietary carbohydrate content affects the efficacy of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type… read more here.
Keywords: ipragliflozin; sglt2 inhibitor; carbohydrate; diabetic mice ... See more keywords
THE SGLT2 INHIBITOR EMPAGLIFLOZIN CAUSES A GREATER REDUCTION IN SKIN SODIUM CONTENT AND INTERSTITIAL VOLUME THAN LOOP DIURETICS IN HEART FAILURE
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31702-2
Abstract: The classic view that sodium (Na) in the extracellular volume (both intravascular and interstitial spaces) is in equilibrium has been recently challenged with the discovery of skin Na storage at higher concentrations than in blood.… read more here.
Keywords: volume; causes greater; sglt2 inhibitor; sodium ... See more keywords
Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients.
Sign Up to like & getrecommendations! Published in 2018 at "Drug research"
DOI: 10.1055/s-0043-123465
Abstract: In patients with type 2 diabetes mellitus who show suboptimal blood glucose control under insulin therapy alone, concomitant treatment with an additional hypoglycemic agent that differs in its mechanism of action from insulin may be… read more here.
Keywords: insulin; inhibitor; sglt2 inhibitor; type diabetic ... See more keywords
A4480 Chronic treatment with a SGLT2 inhibitor does not activate systemic and intrarenal renin-angiotensin system in CKD rats
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Hypertension"
DOI: 10.1097/01.hjh.0000548058.43048.be
Abstract: Objectives: We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin-angiotensin system (RAS) activity in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD).… read more here.
Keywords: systemic intrarenal; angiotensin; sglt2 inhibitor; angiotensinogen ... See more keywords